Found: 7
Select item for more details and to access through your institution.
A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.845417
- By:
- Publication type:
- Article
Pharmacokinetic/pharmacodynamic data extrapolation models for improved pediatric efficacy and toxicity estimation, with application to secondary hyperparathyroidism.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 6, p. 882, doi. 10.1002/pst.2043
- By:
- Publication type:
- Article
Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation.
- Published in:
- Pharmaceutical Statistics, 2017, v. 16, n. 4, p. 232, doi. 10.1002/pst.1807
- By:
- Publication type:
- Article
OAB-026: MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S17, doi. 10.1016/S2152-2650(21)02100-5
- By:
- Publication type:
- Article
MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S439, doi. 10.1016/S2152-2650(21)01978-9
- By:
- Publication type:
- Article
Poster: MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S252, doi. 10.1016/S2152-2650(21)01578-0
- By:
- Publication type:
- Article
A model-based approach to assess the exposure-response relationship of Lorenzo's oil in adrenoleukodystrophy.
- Published in:
- British Journal of Clinical Pharmacology, 2016, v. 81, n. 6, p. 1058, doi. 10.1111/bcp.12897
- By:
- Publication type:
- Article